| 0800 – 0900 |
Breakfast Satellite Educational Session 1
|
| 0900 – 0940 |
Opening Session
|
| 0900 – 0910 |
Opening address
|
| 0910 – 0940 |
Opening lecture |
| 0940 – 1025 |
Tea Time Satellite Symposium 1
|
| 1025 – 1045 |
Exhibition & Networking
|
| 1045 – 1205 |
Breast Cancer Session I
|
| 1045 – 1105 |
A randomized phase III study comparing epirubicin, docetaxel and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early HER-2 negative breast cancer and comparing EDC ±trastuzumab to ED ± trastuzumab as neoadjuvant treatment for early HER-2 positive breast cancer: Fina lresults of ABCSG-24
|
| 1105 – 1125 |
Efficacy of BSI-201, a poly (ADP-ribose) Polymerase-1 (PARP1) inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Patients with Metastatic Triple Negative Breast Cancer (TNBC): Results of a Randomized Phase 2 Trial
|
| 1125 – 1145 |
Comparative data of chemotherapy alone or with sequential addition of trastuzumab in the NCCTG N9831adjuvant trial
|
| 1145 – 1205 |
Q&A Session |
| 1210 – 1320 |
Lunch Satellite Symposium 1
|
| 1320 – 1435 |
Breast Cancer Session II
|
| 1320 – 1340 |
Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial
|
| 1340 – 1400 |
Adjuvant radiation therapy benefits breast cancer patients with 1 to 3 positive lymph nodes undergoing a modified radical mastectomy and systemic therapy
|
| 1400 – 1420 |
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC).
|
| 1420 – 1435 |
Q&A Session
|
| 1435 – 1520 |
Tea Time Satellite Symposium 2 |
| 1520 – 1550 |
Exhibition & Networking
|
| 1550 – 1705 |
Gastrointestinal Cancer Session I
|
| 1550 – 1610 |
Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicentre, randomised phase III trial (the UK ABC-02 trial)
|
| 1610 – 1630 |
A randomized, double-blind, placebo-controlled, multicenter phase 3 trial of everolimus + octreotide inpatients with advanced carcinoid tumors (RADIANT-2)
|
| 1630 – 1650 |
A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial
|
| 1650 – 1705 |
Q&A Session |
| 1705 – 1840 |
Miscellaneous SessionI
|
| 1705 – 1725 |
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study
|
| 1725 – 1745 |
Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC)
|
| 1745 – 1805 |
Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients
|
| 1805 – 1825 |
A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix
|
| 1825 – 1840 |
Q&A Session |
| 1900 – 2030 |
Dinner Satellite Educational Session 1
|
| Program is correct at time of release and is subjected to changes. 11 June 2009 |
| |
| |
| • Download for the scientific programme guide click here |
